British Medical Bulletin 50:718-731 (1994)
© 1994 The British Council
research-article |
Metabolic polymorphisms in carcinogen metabolising enzymes and cancer susceptibility
Imperial Cancer Research Fund, Molecular Pharmacology Unit, Biomedical Research Centre, Ninewells Hospital and Medical School Dundee, UK
Imperial Cancer Research Fund, Cancer Epidemiology Unit Radcliffe Infirmary, Oxford, UK
Abstract
Molecular genetic analysis is providing us with enormous advances in understanding the pathogenesis of human diseases such as cancer. The study of familial disease and the subsequent mapping and identification of the mutations which contribute to disease susceptibility, is not only providing insights into the factors involved in the pathogenesis of the disease but also identifying new targets for therapy.
It is now clear that human tumours result from a complex sequence of mutation events. Each individual step makes the mutated cell more independent of its normal growth regulatory processes, eventually resulting in the formation of a metastatic tumour. There are a multitude of biochemical changes that these mutations confer, which provide preneoplastic cells with a selection advantage. In addition to an increased rate of cell division, such changes may make the cells resistant to cytotoxic insult or to programmed cell death. They can also confer an increased ability to survive independent of a normal hormonal environment. It is now clear that all these types of change may contribute to tumour cell progression.
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
K M Fong, Y Sekido, A F Gazdar, and J D Minna Lung cancer * 9: Molecular biology of lung cancer: clinical implications Thorax, October 1, 2003; 58(10): 892 - 900. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Sachse, G. Smith, M. J.V. Wilkie, J. H. Barrett, R. Waxman, F. Sullivan, D. Forman, D. T. Bishop, and C.R. Wolf A pharmacogenetic study to investigate the role of dietary carcinogens in the etiology of colorectal cancer Carcinogenesis, November 1, 2002; 23(11): 1839 - 1850. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. I. O. Garner, E. E. Stokes, R. S. Berkowitz, S. C. Mok, and D. W. Cramer Polymorphisms of the Estrogen-metabolizing Genes CYP17 and Catechol-O-methyltransferase and Risk of Epithelial Ovarian Cancer Cancer Res., June 1, 2002; 62(11): 3058 - 3062. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. M. Fong, Y. Sekido, and J. D. Minna MOLECULAR PATHOGENESIS OF LUNG CANCER J. Thorac. Cardiovasc. Surg., December 1, 1999; 118(6): 1136 - 1152. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Lechevrel, A. G. Casson, C. R. Wolf, L. J. Hardie, M. B. Flinterman, R. Montesano, and C. P. Wild Characterization of cytochrome P450 expression in human oesophageal mucosa Carcinogenesis, February 1, 1999; 20(2): 243 - 248. [Abstract] [Full Text] [PDF] |
||||



